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DEVELOPMENT OF SULFHYDRYL-REACTIVE SILICA FOR
PROTEIN IMMOBILIZATION IN HIGH-PERFORMANCE AFFINITY
CHROMATOGRAPHY
Rangan Mallik, Chunling Wa, and David S. Hage*
Chemistry Department, University of Nebraska, Lincoln, NE 68588-0304 (USA)
Abstract
Two techniques were developed for the immobilization of proteins and other ligands to silica through
sulfhydryl groups. These methods made use of maleimide-activated silica (the SMCC method) or
iodoacetyl-activated silica (the SIA method). The resulting supports were tested for use in high-
performance affinity chromatography by employing human serum albumin (HSA) as a model protein.
Studies with normal and iodoacetamide-modified HSA indicated that these methods had a high
selectivity for sulfhydryl groups on this protein, which accounted for the coupling of 77–81% of this
protein to maleimide- or iodacetyl-activated silica. These supports were also evaluated in terms of
their total protein content, binding capacity, specific activity, non-specific binding, stability and
chiral selectivity for several test solutes. HSA columns prepared using maleimide-activated silica
gave the best overall results for these properties when compared to HSA that had been immobilized
to silica through the Schiff base method (i.e., an amine-based coupling technique). A key advantage
of the supports developed in this work is that they offer the potential of giving greater site-selective
immobilization and ligand activity than amine-based coupling methods. These features make these
supports attractive in the development of protein columns for such applications as the study of
biological interactions and chiral separations.
INTRODUCTION
High-performance affinity chromatography (HPAC) is a method of growing interest for the
selective separation and analysis of various chemicals.1–4 This technique makes use of a
support such as HPLC-grade silica that contains a biologically-related molecule as the affinity
ligand, or stationary phase. HPAC has been used in such applications as the study of biological
interactions, biomolecule purification, chiral separations, and the analysis of clinical,
biological and environmental samples.5–14 Advantages of HPAC for these applications
include its high specificity, speed, ease of automation and ability to use the same ligand for
multiple applications1–3,15.
An important factor to consider in the production of a column for HPAC is the way in which
the affinity ligand is attached to the chromatographic support.16–18 When a protein is utilized
as the affinity ligand, this attachment often involves the use of a diol- or glycol-containing
support (e.g., diol-bonded silica)19 and amine-based coupling techniques such as the Schiff
base,20–26 carbonyldiimidazole,27–31 cyanogen bromide,32 succinimidyl ester32,33 or
epoxy immobilization methods.34–39 It is also possible with HPLC supports to attach proteins
to amine-activated supports by using the glutaraldehyde32,33 or N-hydroxysuccinimide (NHS)
methods.32,33,38,40 In addition, glycoproteins can be immobilized after oxidation of their
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carbohydrate residues by reacting such proteins with hydrazide- or amine-containing supports.
32,33,36
Human serum albumin (HSA) is one protein that is often used in HPAC columns. HSA is the
most abundant protein in blood and is known to bind a variety of drugs and biological
compounds.41–43 When immobilized in an HPAC column, this protein can be used under
isocratic conditions as a weak-to-moderate ligand for the study of drug-protein
interactions44 or as a stationary phase for separating a variety of chiral solutes.19 Most
previous work with HSA has involved its immobilization to HPLC supports through its amine
groups; however, HSA has a large number of primary amines in its structure (i.e., 58 lysines
plus the N-terminal amine)42 which might lead to such undesirable effects as multipoint
attachment, improper orientation or inactivation of this protein during the immobilization
process.32
An alternative route that is appealing for the immobilization of HSA and other proteins is to
use free thiol groups in their structures. For instance, normal HSA has only a single free thiol
(Cys-34) which could, in theory, be used for the single point attachment of this protein to a
support. This study will explore two approaches for such work based on maleimide- and
iodoacetyl-activated materials.32,33,45–49 Both maleimide and iodoacetyl groups are thought
to react selectively with the sulfhydryl group of cysteine.32,33,45–49 In addition, these
reactions are known to be fast for small thiol-containing compounds,45–49 making this a
possible route for the rapid immobilization of proteins like HSA to HPLC supports.
Immobilization based on maleimide and iodoacetyl groups has been used in the past for
coupling proteins and peptides to quartz disks,50 polished silicon wafers,50 poly(allylamine)
polymers,51 polystyrene microspheres,52 and Sepharose.46 However, this approach has not
yet been used with any HPLC supports. This study will explore the use of these coupling
methods with HSA and HPLC-grade silica. The supports used in this work will be prepared
by reacting aminopropyl silica with N-(4-carboxycyclohexylmethyl) malemide (SMCC) or
succinimidyl iodoacetate (SIA), as shown in Figure 1. This should give activated materials
with good stability towards hydrolysis.33,45–49 After these supports have been developed,
they will be compared in terms of their specificity for sulfhydryl groups and their ability to
immobilize HSA in an active form for use in drug-binding studies and chiral separations. The
results will then be compared with those noted for the Schiff base method, a common amine-
based coupling technique employed for HSA and other proteins.20–26,53
EXPERIMENTAL SECTION
Reagents
The SMCC (>99% pure; toxic), succinimidyl iodoacetate (>97% pure; toxic) and Slide-A-
Lyzer dialysis cassettes (7 kDa MW cutoff, 0.1–0.5 mL or 0.5–3 mL capacity) were from Pierce
(Rockford, IL, USA). The D-tryptophan (>99% pure), dimethyl formamide (DMF, 99% pure),
acetonitrile (HPLC grade, >99.93% pure; flammable), formic acid (96% pure; corrosive),
trifluoroacetic acid (TFA, >99% pure; corrosive), acetic anhydride (>99% pure; flammable)
and pyridine (>99% pure; flammable and corrosive) were from Aldrich (Milwaukee, WI,
USA). HSA (Cohn fraction V, essentially fatty acid free), 3-(α-acetonylbenzyl)-4-
hydroxycoumarin (racemic warfarin, >98% pure; toxic and possible teratogen), racemic
tryptophan (>99% pure), L-tryptophan (>98% pure), ibuprofen (> 98% pure), carbamazepine
(>98% pure), 4-dimethylaminopyridine (DMAP; toxic), trypsin (sequencing grade), guanidine
hydrochloride (> 99% pure), dithiothreitol (DTT, >99% pure), iodoacetamide (99% pure; light
sensitive) and Lcysteine hydrochloride (anhydrous, >98% pure; toxic) were from Sigma (St.
Louis, MO, USA). Ethylenediamine tetraacetic acid (EDTA, disodium salt and dihydrate,
essentially 100% pure) was purchased from J. T. Baker (Phillipsburg, NJ, USA). The separate
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forms of R- and Swarfarin (>98% pure) were from DuPont Pharmaceuticals (Wilmington,
Delaware, USA).
The thiol and sulfide quantitation kit (T-6060) was purchased from Molecular Probes (Eugene,
OR, USA); this kit contained the N-benzoyl-L-arginine, p-nitroanilide (L-BAPNA), papain-
S-S-CH3, and L-cysteine referred to later in this section. The aminopropyl and bare silica
Nucleosil Si-300 supports (both 7 μm particle diameter, 300 Å pore size) were from Macherey
Nagel (D ren, Germany). All aqueous solutions were prepared using water from a Nanopure
system (Barnstead, Dubuque, IA, USA) and filtered using Osmonics 0.22 μm nylon filters from
Fisher (Pittsburgh, PA, USA).
Apparatus
The system used in the chromatographic studies consisted of a P4000 gradient pump and a
UV100 absorbance detector from Thermoseparations (Riviera Beach, FL, USA). Samples were
injected using a Rheodyne LabPro valve (Cotati, CA, USA) equipped with a 20 μL sample
loop. Chromatographic data were collected and processed using in-house programs written in
LabView 5.1 (National Instruments, Austin, TX, USA). Assays for determining the stability
of the activated silica were performed using a Shimadzu UV-160A spectrophotometer (Kyoto,
Japan). All HPLC columns were packed using an Alltech column slurry packer (Deerfield, IL,
USA). Fourier transform infrared (FTIR) spectroscopy was performed using a Nicolet
AVATAR-360 instrument from the Thermo Electron Corporation (Waltham, MA, USA); the
FTIR work was conducted using dried silica samples (approximately 10 mg) and 128 scans
per analysis in the DRIFT mode. Elemental analysis of the silica samples was performed by
Midwest Microlab (Indianapolis, IN, USA).
Preparation of maleimide-activated silica (SMCC method)
The general scheme used in the SMCC method to prepare maleimide-activated silica is shown
in Figure 1(a). This approach was adapted from previous work described for the reaction of
amines with NHS-activated compounds.33,45,46,54 In this method, 0.8 g of aminopropyl
Nucleosil Si-300 was first dried in a vacuum oven for 24 h. A 24 mg portion of DMAP and 50
mg of SMCC were next dissolved in 5 mL of dry DMF. The dried aminopropyl silica was
added to this solution and shaken in the dark at room temperature for 24 h (note: similar work
in the activation of aminopropyl Nucleosil Si-300 with disuccinimidyl suberate indicated that
a reaction time of 8 hr is sufficient for completion of this reaction).40 The resulting maleimide-
activated silica was collected by centrifugation and washed ten times with DMF. Prior to
immobilization, the maleimide-activated silica was washed three times with pH 7.0, 1.3 M
potassium phosphate buffer and used immediately. A small portion of the maleimide-activated
silica was set aside for later analysis, being washed ten times with DMF, five times with
acetonitrile, and five times with diethyl ether; this support was then dried under vacuum at
room temperature and stored in the dark at 4°C until use. The maleimide-activated silica was
found to be stable for more than 2 months under these storage conditions.
Early work in this report used the maleimide-activated silica directly for protein
immobilization. However, later studies used an additional pretreatment step to reduce the
effects of unreacted aminopropyl groups on non-specific binding. These aminopropyl groups
were capped by reacting them with acetic anhydride to produce acetamide groups. This was
performed after support activation by taking 0.5 g of the maleimide-activated silica and adding
it to 4 mL of a 1:1 mixture of acetic anhydride and pyridine containing 100 mg of DMAP. This
mixture was stirred in the dark for 24 h at room temperature. The capped silica was then washed
five times with acetonitrile, three times with diethyl ether, and dried overnight under vacuum.
This support was then used for the immobilization of HSA or used directly as a control material.
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The conditions used for the immobilization of HSA to maleimide-activated silica were adapted
from a previous method reported for the conjugation of antibody Fab’ fragments to horseradish
peroxidase.45 Maleimide groups are known to react preferentially with sulfhydryl groups over
the pH range of 6.5–7.5; this forms a stable carbon-sulfur linkage,33,45 as shown in Figure 1
(a). Prior to its use in immobilization, the maleimide-activated silica was washed three times
with pH 7.0, 1.3 M potassium phosphate buffer. A 5 mL solution of 15 mg/mL HSA in pH 7.0,
1.3 M potassium phosphate buffer was then added to roughly 0.8 g of the activated silica; this
solution was degassed by sonication for 5 min and allowed to react with shaking at 4°C for 36
h. The support was later separated from the rest of the reaction mixture by centrifugation and
was washed five times with pH 7.0, 1.3 M potassium phosphate buffer. The final support was
stored for up to two days in pH 7.4, 0.067 M potassium phosphate buffer at 4 ºC prior to being
placed into a column. A control support was prepared in a similar manner by combining 5 mL
of 10 mM cysteine (instead of HSA) in pH 7.0, 1.3 M potassium phosphate buffer with
approximately 0.4 g of dry malemide-activated silica.
When using maleimide-activated silica with uncapped aminopropyl groups, there was some
HSA that was initially adsorbed non-covalently to the support’s surface. The HSA adsorbed
on aminopropyl silica was measured using a reducing agent compatible BCA assay from Pierce.
It was found that most of this adsorbed HSA could be removed by performing extensive
washing of the support after the immobilization step or by capping the aminopropyl groups
with acetic anhydride prior to immobilization. The first of these approaches involved the
application of 180 or more column volumes of pH 7.4, 0.067 M potassium phosphate buffer
to each HSA column prior to its use in chromatographic studies. After this washing it was
estimated that less than 7.7 to 7.8 mg of HSA/g of silica was still adsorbed in columns prepared
by the SMCC or SIA methods, compared to total protein contents of 61.2 and 20.6 mg HSA/
g silica, respectively.
Preparation of iodoacetyl-activated silica (SIA method)
The reaction used in the SIA method for preparing iodoacetyl-activated silica is shown in Figure
1(b). The conditions used in this work with silica were adapted from previous methods
described for the reaction of amines with NHS-activated reagents.33,45,46,54 In this study,
0.8 g of aminopropyl Nucleosil Si-300 was dried under vacuum for 24 h to remove any residual
water. A 25 mg portion of DMAP and 50 mg of SIA were then dissolved in 5 mL of dry DMF.
The aminopropyl Nucleosil Si-300 was added to this solution and shaken in the dark at room
temperature for 24 h (i.e., a time period over three-fold longer than that estimated to be
necessary for completion of the activation reaction).40 The resulting activated support was
removed from the reaction mixture by centrifugation and was washed ten times with DMF. A
portion of this support was washed three times with pH 8.3, 0.050 M borate buffer containing
5 mM EDTA before its use in immobilization. Another portion of the same support was set
aside for later analysis after being washed ten times with DMF, five times with acetonitrile,
and five times with diethyl ether, followed by drying under vacuum at room temperature and
storage in the dark at 4°C. The iodoacetyl-activated silica was found to be stable for at least 2
months under these storage conditions. Early experiments in this report used the iodoacetyl-
activated silica directly for HSA immobilization, but later studies used this support after it had
been reacted with acetic anhydride to remove unreacted aminopropyl groups (performed in the
same manner as described for the SMCC method).
The conditions used for the immobilization of HSA to iodoacetyl-activated silica were adapted
from an earlier reference,33 which describes the reaction of sulfhydryls with iodoacetyl groups.
Iodoacetyl groups are known to react preferentially with sulfhydryl groups under basic
conditions (pH > 8) to form a stable carbon-sulfur linkage.33,47 Prior to immobilization, the
iodoacetyl-activated silica was washed three times with pH 8.3, 0.050 M borate buffer
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containing 5 mM EDTA.33,55 A 5 mL solution of 15 mg/mL HSA in pH 8.3, 0.050 M borate
buffer containing 5 mM EDTA was then added to the iodoacetyl-activated silica and degassed
with sonication for 5 min. The immobilization reaction was allowed to occur with stirring at
4°C for 42 h. The final support was separated from the rest of the reaction mixture by
centrifugation and washed five times with pH 8.3, 0.050 M borate buffer containing 5 mM
EDTA, followed by five additional washings with pH 7.4, 0.067 M potassium phosphate buffer.
This immobilized HSA support was stored in pH 7.4, 0.067 M potassium phosphate buffer at
4°C until use. A control support was prepared under similar conditions by immobilizing
cysteine in place of HSA to the iodoacetyl-activated silica; in this case, 0.4 g of dry iodoacetyl-
activated silica was combined with 5 mL of a 10 mM cysteine solution in pH 8.3, 50 mM borate
buffer containing 5 mM EDTA. As stated earlier for the SMCC method, most of the HSA that
was non-covalently adsorbed to the support was removed by either performing extensive
washing of this material before use or by capping remaining aminopropyl groups on this
support with acetic anhydride prior to immobilization.
Schiff base immobilization method
The conditions used for the immobilization of HSA to silica by the Schiff base method were
adapted from Ref. 53, with all reactions being carried out at room temperature unless otherwise
indicated. In this approach, 1 g of bare silica Nucleosil Si-300 was combined with 0.2 mL of
3-glycidoxypropyltrimethoxysilane in 8.5 mL of 0.10 M, pH 5.5 sodium acetate buffer. This
mixture was heated at 90°C for 5 h with shaking. The resulting epoxy silica was washed three
times with water and two times with a pH 3.0 solution of sulfuric acid in water. This silica was
refluxed with 100 mL of a pH 3.0 sulfuric acid solution in water for 1 h. The resulting diol-
bonded silica was washed three times with water and three times with a 90% solution of acetic
acid in water. This silica was then combined with 1 g of sodium periodate (an oxidizing agent)
in 20 mL of the 90% acetic acid solution and allowed to react for 2 h with shaking. The resulting
aldehyde-activated silica was washed six times with water and twice with 0.10 M, pH 6.0
potassium phosphate buffer.
Immediately after its preparation, the aldehyde-activated silica was combined with 5 mL of
0.10 M, pH 6.0 potassium phosphate buffer, 100 mg HSA and 50 mg sodium cyanoborohydride
(a mild reducing agent). This mixture was allowed to react with shaking for four days at 4°C.
Any remaining aldehyde groups on the silica were then reduced by slowly adding 0.025 mg
sodium borohydride (a strong reducing agent) in 10 mL of pH 8.0, 0.10 potassium phosphate
buffer. This support was stored in 0.067 M, pH 7.4 potassium phosphate buffer at 4°C until
use. The control support for this material was prepared following the same procedure as
described above with no HSA being added during the immobilization reaction.
Analysis of support activation and stability
A modified version of a papain-based assay56–58 was used to determine the degree of
modification and stability of the maleimide- and iodoacetyl-activated supports. This assay was
performed as shown in Figure 2. In this method, a known excess of cysteine was added to each
activated support and allowed to react. Later, the remaining unreacted cysteine was combined
with papain-S-S-CH3, which transformed the inactive form of papain into an active form
(papain-SH). The activity of the papain-SH was then measured by using L-BAPNA as a
chromogenic substrate.
This assay was performed by placing a known mass (0.7–0.9 mg) of each activated support
into a 5 mL test tube. To each test tube was added (1) 7.5 μL of 0.5 mM cysteine in 5 mM
sodium acetate buffer containing 50 mM sodium chloride and 0.5 mM EDTA, (2) 7.5 μL of 5
mM sodium acetate buffer containing 50 mM sodium chloride and 0.5 mM EDTA, and (3)
220 μL of pH 7.6, 40 mM sodium phosphate buffer containing 2 mM EDTA. Control samples
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containing no cysteine were prepared in a similar manner by adding a known mass of each
activated support (0.7–0.9 mg) to (1) 15 μL of 5 mM sodium acetate buffer containing 50 mM
sodium chloride and 0.5 mM EDTA, and (2) 220 μL of pH 7.6, 40 mM sodium phosphate
buffer containing 2 mM EDTA. These solutions were then slowly mixed by a magnetic stirrer
and allowed to react at room temperature for 40 min.
A 0.5 mL portion of 0.6 mg/mL papain-S-S-CH3 in pH 4.0, 5 mM sodium acetate buffer was
next added to each test tube. These new mixtures were allowed to react for 1 h at room
temperature while being slowly mixed by a magnetic stirrer. After this reaction, 0.5 mL of a
4.9 mM L-BAPNA solution in pH 6.3, 50 mM bis-Tris buffer and 1 mM EDTA was added in
30 s intervals to the test tubes, which were reacted for another 1 h with stirring at room
temperature. The final reaction mixtures were filtered in 30 s intervals using a 0.2 μm nylon
syringe filter from Pall (Ann Arbor, MI, USA) and measured for their absorbance at 410 nm.
Nanopure water was used as the reference during these measurements. The absorbance of each
control sample (i.e., mixtures with no cysteine added) was subtracted from the absorbance of
the corresponding unknown sample. This difference in absorbance was used with a calibration
curve to determine the amount of maleimide or iodoacetyl groups that was on the activated
support.
The calibration curve used in this assay was constructed by using standards that contained
known amounts of cysteine. These standards were prepared by adding to a series of test tubes
0, 4, 8, 12 or 15 μL of a 0.1 mM cysteine solution in 5 mM sodium acetate buffer containing
50 mM sodium chloride and 0.5 mM EDTA. All of these solutions were brought to a total
volume of 15 μL by adding 5 mM sodium acetate buffer containing 50 mM sodium chloride
and 0.5 mM EDTA. These solutions were mixed and incubated for 40 min at room temperature.
A 0.5 mL aliquot of 0.6 mg/mL papain-S-S-CH3 in pH 4.0, 5 mM sodium acetate buffer was
then added to each standard. This solution was allowed to react for 1 h at room temperature
with slow mixing by a magnetic stirrer. Next, 0.5 mL of 4.9 mM L-BAPNA in pH 6.3, 50 mM
bis-Tris buffer and 1 mM EDTA was added in 30 s intervals to the test tubes and allowed to
react for 1 h with slow mixing by a magnetic stirrer. The absorbance measurements of these
solutions were taken in 30 s intervals at 410 nm using water as a reference and were plotted
versus the original cysteine concentration to give a calibration curve. This method had a limit
of detection of approximately 0.2 μM cysteine (S/N = 3), with a linear range that extended up
to 1.5 μM cysteine.
Preparation of iodoacetamide-modified HSA
The iodoacetamide-modified HSA (used later in this work to evaluate the immobilization
selectivity of the maleimide- or iodoacetyl-activated silica) was prepared by combining 68 mg
of iodoacetamide in 337 μL of 1 M NaOH with 7.5 mL of a 15 mg/mL HSA solution in pH
8.2, 0.1 M ammonium carbonate buffer (i.e., a mole ratio of approximately 200:1 for
iodoacetamide versus HSA). This solution was shaken for 30 min in the dark at room
temperature; this solution was then divided into one 0.5 mL and two 3 mL portions. The 0.5
mL portion was placed into a 0.1–0.5 mL dialysis cassette and dialyzed twice for 4 h at room
temperature against two 1 L portions of water; this was followed by dialysis of the same solution
against 1 L of pH 8.2, 100 mM ammonium bicarbonate buffer for 12 h at room temperature
and later analysis of this solution by MALDI-TOF mass spectrometry (performed at the
Nebraska Center for Mass Spectrometry, Lincoln, NE).
The two 3 mL portions of the iodoacetamide-modified HSA solution were placed into two 0.5–
3 mL dialysis cassettes and dialyzed twice for 4 h at room temperature against two 1 L portions
of water. One of these dialysis cassettes was then placed in 1 L of pH 7.0, 100 mM potassium
phosphate buffer for an additional 12 h of dialysis at room temperature. This solution was later
used for the immobilization of iodoacetamide-modified HSA onto maleimide-activated silica.
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The other dialysis cassette was placed in 1 L of pH 8.3, 100 mM sodium borate buffer
containing 50 mM EDTA for 12 h at room temperature. After dialysis, this solution was used
for the immobilization of iodoacetamide-modified HSA with the iodoacetyl-activated silica.
Chromatographic studies
All HSA supports and control supports prepared in this study were placed into separate 4.6
mm I.D. × 5 cm stainless steel columns. These supports were downward slurry packed at 3500
psi (24 MPa) for 40 min and at room temperature using a column packer from Alltech
(Deerfield, IL, USA) and pH 7.4, 0.067 M potassium phosphate buffer as the packing solution.
All mobile phases were degassed under vacuum for at least 30 min prior to use. All
chromatographic studies were performed at 25 (± 0.5)ºC with the columns being enclosed in
water jackets for temperature control.
The frontal analysis studies were performed by applying 2.5–30 μM carbamazepine in 0.067
M, pH 7.4 potassium phosphate buffer to the HSA columns and control columns. This was
typically performed at 0.5 mL/min and 25°C using an approach similar to that described in
Ref. 59 (Note: similar results to those seen at 0.5 mL/min were obtained at flow rates ranging
from 0.3–1.0 mL/min, with a variation of less than 7% being noted over this range of conditions
in the moles of carbamazepine that were required to reach the mean point of the breakthrough
curve at any given concentration of this analyte). The elution of carbamazepine was monitored
by absorbance detection at 214 nm. The columns were first equilibrated in pH 7.4, 0.067 M
potassium phosphate buffer for 30 min, with a switching valve then being used to apply the
desired carbamazepine solution. After each frontal analysis study, pH 7.4, 0.067 M potassium
phosphate buffer was applied at 0.5 mL/min for 30 min (SIA supports) to 1 h (SMCC supports)
to elute any retained carbamazepine prior to the next study. The resulting breakthrough curves
were analyzed according to methods described in Ref. 44 to estimate the association
equilibrium constants and binding capacities for carbamazepine on the HSA columns. The
results obtained in identical experiments on the control columns were used to correct for the
void time of the system and for any non-specific binding of carbamazepine to the support. The
non-specific binding of carbamazepine to uncapped supports in the SMCC and SIA columns
was estimated to be 64–74% and 69–72% of the total binding capacity when HSA was present.
After acetic anhydride was used to cap aminopropyl groups on these supports, this non-specific
binding was reduced by 20% for carbamazepine and by 80% in studies using warfarin as the
analyte.
The sample for the zonal elution studies of D/L-tryptophan was prepared fresh daily in the
desired mobile phase and contained 20 μM of this analyte. Solutions of R/S-ibuprofen and R/
S-warfarin (20 μM) for zonal elution studies were prepared in the desired mobile phase and
used over the course of less than a week. Three 20 μL injections were made of each sample
for each experiment. No appreciable changes in retention factors (i.e., random variations of
less than 1%) were noted when using up to three-fold higher sample concentrations, indicating
that linear elution was present under the zonal elution conditions used in this study. The flow
rates used during the separation of D/L-tryptophan, R/S-ibuprofen and R/S-warfarin on the
maleimide-activated HSA columns were 1.5, 1.0 and 1.0 mL/min, respectively. The flow rates
used during the separation of these same solutes on the iodoacetyl-activated HSA columns
were 0.3, 0.5 and 0.3 mL/min. The column backpressures under these conditions ranged from
78 psi (0.54 MPa) at 0.3 mL/min to 500 psi (3.4 MPa) at 1.5 mL/min. No measurable changes
(i.e., random variations of less then 2%) were seen in the measured retention factors at either
lower or higher flow rates (0.3–1.5 mL/min), as noted previously with other silica-based HSA
columns.7
The following wavelengths were used for detection in the zonal elution studies: D/L-
tryptophan, 280 nm; R/S-ibuprofen, 225 nm; and R/S-warfarin, 310 nm. The following mobile
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phases were selected for use in the zonal elution studies based on previous separations that
have been reported for the given analytes on HSA columns: D/L-tryptophan, pH 7.4, 0.067 M
potassium phosphate buffer;7 R/S-ibuprofen, pH 7.0, 0.067 M potassium phosphate buffer
containing 8% isopropanol and 5 mM octanoic acid; R/S-warfarin, pH 7.0, 0.067 M potassium
phosphate buffer containing 5% isopropanol and 1 mM octanoic acid. In the last two cases,
isopropanol and octanoic acid were used as mobile phase modifiers or competing agents to
adjust and lower the retention factors for the injected analytes to a reasonable range, as
described for other HSA columns.60–63
The system void time was determined by injecting 20 μL of 5 μM dimethyl sulfoxide (DMSO)
onto the chromatographic system while monitoring the absorbance at 205 nm. The extra-
column void time was similarly determined by injecting DMSO onto the chromatographic
system after replacing the column with a zero dead volume connector. All the retention times
and peak widths were determined by using moment analysis or the B/A0.5 method.64
RESULTS AND DISCUSSION
Initial evaluation of maleimide- and iodoacetyl-activated supports
The silica supports that were activated by the SMCC and SIA methods were first examined
qualitatively by FTIR spectroscopy. Some typical spectra that were obtained are shown in
Figure 3. The spectrum for the original aminopropyl silica contained major absorbance bands
at 831, 1058, 1309 and 1574 cm−1. These bands are due to the Si-C, Si-O-Si or C-N stretches
and the primary amine groups in this material, respectively.65 Silica activated by the SMCC
method also had these bands (due to remaining aminopropyl groups) as well as the following
additional absorbance bands (with tentative assignments given in parentheses): 797 cm−1 (due
to an alkene group coupled to an amide); 1045 cm−1 (from the cyclohexane group in the –
CH2- region); 1504 cm−1 (due to an peptide amide bond, NH[δ] and N-CO stretch); 1712
cm−1 (due to an amide coupled to an alkene); and 1766 cm−1 (due to an amide). Silica activated
by the SIA method had similar peaks at 1504 cm−1 (due to the peptide amide bond, NH[δ] and
N-CO stretch) and 1779 cm−1 (due to an amide group).65 These results indicated that the
SMCC and SIA methods were successful in activating at least part of the aminopropyl groups
on the starting material.
The degree of support activation in the SMCC and SIA methods was examined in a more
quantitative manner by employing elemental analysis. This was accomplished by measuring
the nitrogen and iodine content of the maleimide- and iodoacetyl-activated supports,
respectively. It was found that activation of aminopropyl silica by the SMCC method under
the conditions used in this work gave 14.3 (± 7.1) μmol maleimide groups per gram of silica
for Nucleosil Si-300. Activation of the same original aminopropyl silica by the SIA method
gave 13.4 (± 0.8) μmol iodoacetyl groups per gram of silica. Both of these values are
comparable to the extent of activation that has been reported for reaction of the same type of
aminopropyl silica with N-hydroxysuccinimide, which gave 12 μmol NHS groups per gram of
silica.40 This similarity is not surprising since the NHS activation process involves a
nucleophilic reaction of amine groups with disuccinimidyl suberate,40 which is closely related
to the types of reactions that were used for support activation in this current study.
The amount of activated sites versus the total aminopropyl sites on the original supports was
also determined. In this case, the original support was known to contain 328 (± 7) μmol
aminopropyl groups per gram of silica. This meant that the maleimide groups placed on this
support in the SMCC method gave rise to activation of only 4.4% of these sites. In the SIA
method, 4.1% of these sites were activated with iodoacetyl groups. These values are similar to
those reported with the same support when activating it with NHS, where 1.3% activation was
reported.40 However, up to 150 μmol activated groups per gram of silica has been reported in
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a study using 7 μm, 60 Å pore size aminopropyl silica that had been activated using succinic
anhydride.66 This difference is due, in part, to the higher surface area and larger amount of
aminopropyl groups on 60 Å versus 300 Å pore size silica, which accounts for approximately
50% of this difference in activation. The remaining difference is believed to be the result of 1)
hydrolysis of SMCC and SIA during the activation reaction and 2) the use of a lower mole
ratio in this work for the activating reagent versus aminopropyl groups (i.e., 0.57–0.67
compared to 0.85 in Ref. 66).
In this study support activation was typically performed using 187 μmol SMCC or 221 μmol
SIA per gram of aminopropyl silica, which gave a mole ratio of 0.57–0.67 for these agents
versus aminopropyl groups on the support. The fact that this mole ratio was below 1.0 partly
explains why not all of the aminopropyl groups were activated. Although a larger excess of
activating agent could have been used, the amount of reagent required to do this would have
been cost prohibitive. In addition, complete activation of the support was not necessary for the
overall goal of this project (i.e., site-selective protein immobilization) since a lower density of
activated sites would be favorable for the coupling of a protein through only one or a few
residues per molecule. This, in turn, would minimize the occurrence of multipoint attachment
and any corresponding deformation of the protein’s tertiary structure.32
The stability of the maleimide- and iodacetyl-activated supports was examined by using both
materials to immobilize cysteine. This was accomplished by monitoring the amount of cysteine
that was immobilized on each support before and after storage. No significant change was
noted in the amount of cysteine that could be immobilized onto freshly-prepared maleimide-
activated silica (after storage in the dark at 4°C for 2 days) and the same support after it had
been stored in the dark for over 65 days at room temperature; the amount of immobilized
cysteine on these supports was 4.02 (± 0.07) and 4.00 (± 0.06) μmol per gram of silica,
respectively. No noticeable change was also seen in the amount of cysteine that could be
immobilized on the iodoacetyl-activated silica after storage in the dark at 4 ºC for 2 days and
after storage in the dark at room temperature for 65 days, giving values of 4.25 (± 0.03) and
4.35 (± 0.05) μmol per gram of silica, respectively.
Use of supports in protein immobilization
It was found through protein assays that both the maleimide- and iodoacetyl-activated supports
could be used to couple a model protein (HSA) to silica. This is illustrated in Figure 4, which
shows how the overall extent of protein immobilization varied with reaction time when using
1.5 mL of a 15 mg/mL solution of HSA that was combined with approximately 0.15 g of
activated support (slurry concentration, approximately 100 mg silica/mL, where the support
had not been previously capped to remove aminopropyl groups). The amount of HSA in this
mixture was approximately 1.9-fold larger than that needed to obtain monolayer coverage of
this protein, based on a surface area for HSA of 40 nm2.
Both the SMCC and SIA methods required about one day for the immobilization of HSA under
these conditions, with 95% of the maximum protein coverage being obtained in 28–30 h.
However, these two methods did differ in the total amount of HSA that was coupled to the
support. The SMCC method gave up to 67.8 (± 1.3) mg HSA/g silica (before correcting for
non-covalent adsorption) after 28 h of immobilization, while the SIA method gave only about
half of this amount, or 27.1 (± 0.5) mg HSA/g silica. After these supports had been packed and
washed with 180 column volumes of the mobile phase (i.e., to remove non-covalently adsorbed
HSA), the observed protein contents for the SMCC and SIA methods were 61.2 (± 1.3) mg/g
and 20.6 (± 0.7) mg/g, respectively.
It was found in further studies with control materials that up to 14.3 mg HSA/g silica in the
SMCC and SIA methods was due to non-covalent adsorption of HSA when using activated
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supports that still contained aminopropyl groups. However, this process could be eliminated
or reduced by first capping these aminopropyl groups with acetic anhydride, as described in
the Experimental Section. The presence of non-covalent adsorption plus covalent
immobilization explains the biphasic nature of the time profiles in Figure 4. Non-covalent
adsorption would be represented by the fast but small levels of immobilization that occurred
during the early stages of this procedure (i.e., at times below 1 h), while the slower but larger
amount of covalent immobilization is probably represented by the increase in protein content
at longer reaction times. The use of capped aminopropyl groups caused a small decrease in
amount of covalent immobilized HSA that could be achieved with each support (e.g., 45.7
(±0.7) mg HSA/g silica in the SMCC method); this effect is probably due to the loss of some
malemide groups on the activated support during the capping process.
The differences found in Figure 4 for the maximum amount of immobilized HSA in the SMCC
and SIA methods is interesting since these techniques gave supports with approximately the
same number of activated sites and similar stabilities. In both cases the same amount of protein
was originally present, but 57% of the added HSA was coupled covalently in the SMCC method
while only 14% was coupled in the SIA method. In comparison, the same amount of protein
and support in the Schiff base method resulted in 49% of the protein being immobilized, giving
a final coverage of 49.4 (± 5.5) mg HSA/g silica. This latter amount is similar to that reported
in earlier studies using equivalent support and immobilization conditions (i.e., 54 mg HSA/g
support for 300 Å pore size silica).67
The different protein coverages obtained by the SMCC and SIA methods was examined in
more detail by comparing the specificity of these immobilization reactions. This was studied
by comparing the ability of these techniques to immobilize normal HSA and HSA that had
been modified to make its sole free sulfhydryl group non-reactive. The modified HSA was
prepared by treating HSA with iodoacetamide. The modification of the free cysteine group on
this protein was confirmed by comparing MALDI-TOF mass spectra for tryptic digestions of
HSA before and after treatment with iodoacetamide.68 These two protein preparations were
then immobilized under identical conditions to the maleimide- and iodoacetyl-activated
supports. In the SMCC method, the amount of covalently immobilized protein was 81% lower
for the modified HSA than for normal HSA, with values of 10.4 (± 0.7) mg modified HSA/g
silica and 53.5 (± 1.3) mg HSA/g silica, respectively. For the SIA method, the degree of
immobilization for the modified HSA was 77% lower that it was for normal HSA, giving 2.9
(± 0.3) mg modified HSA/g silica versus 12.8 (± 0.5) mg HSA/g silica. This indicated that both
the SMCC and SIA methods were fairly selective in reacting with sulfhydryl groups on HSA
as opposed to other groups on this protein (e.g., amine residues), since the latter would not
have been altered by modification with iodoacetamide.
Activity of immobilized HSA in the SMCC and SIA methods
Another item considered in this study was the amount of active HSA that was obtained by the
SMCC and SIA methods. One way this was assessed was by comparing their binding for
carbamazepine, a probe for the indole-benzodiazepine region of HSA.69 Figure 5 shows the
results of frontal analysis studies that were obtained with this drug on the HSA columns. As
has been noted previously for HSA columns prepared by the Schiff base and NHS methods,
69,70 linear behavior was seen for double-reciprocal plots obtained with the SMCC and SIA
HSA columns (correlation coefficients, 0.996 to 0.999 for n = 5) under the experimental
conditions that were used in this study.
It was possible from the best-fit lines in Figure 5 to estimate the association equilibrium
constant and binding capacity for the major binding site of carbamazepine on HSA.2,69 The
association equilibrium constant determined in this report at pH 7.4 and 25°C was 1.2 (± 0.2)
× 104 M−1 for the binding of carbamazepine to HSA immobilized by the SMCC method and
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1.4 (± 0.6) × 104 M−1 for carbamazepine and HSA immobilized by the SIA method. These
values agreed within one standard deviation with each other and with an association constant
of 1.1 (± 0.2) × 104 M−1 that has previously been reported for the binding of carbamazepine
with HSA immobilized by the Schiff base and NHS methods.69
However, these different immobilization approaches did differ in terms of the amount of active
HSA that was immobilized. For instance, the total binding capacity estimated for HSA in the
SMCC method was 0.80 (± 0.11) μmol carbamazepine/g silica, while the binding capacity for
HSA immobilized by the SIA method was 0.25 (± 0.05) μmol carbamazepine/g silica. This
information was combined with the total amount of immobilized HSA in each column to give
the relative activity of this protein for carbamazepine. This gave a relative activity of 87 (±
11)% for HSA immobilized by the SMCC method and 81 (± 12)% for HSA immobilized by
the SIA method. In comparison, a relative activity of 55–56% has been reported for
carbamazepine when using HSA immobilized by the Schiff base method69,70 and a relative
activity of 37% has been noted for carbamazepine when using HSA immobilized by the NHS
method.70 These results indicated that both the SIA and SMCC methods gave immobilized
proteins with a higher level of activity than common amine-based coupling methods. This is
consistent with a model in which more site-selective attachment and fewer problems due to
random orientation or multipoint attachment are present for HSA that has been immobilized
by the SIA and SMCC methods.
Chromatographic behavior of HSA columns
Additional studies of the SIA and SMCC-prepared HSA columns were performed by using
these to separate various chiral solutes: D/L-tryptophan, R/S-warfarin and R/S-ibuprofen. All
of these solutes have been examined in previous chiral separations using HSA columns
prepared by amine-based coupling methods (e.g., see Refs. 2, 44, 61, 62 and 74); however,
these solutes bind to different regions of HSA. For instance, L-tryptophan is a probe for the
indole-benzodiazepine region of HSA.44,71 The R- and S-enantiomers of warfarin both bind
to the warfarin-azapropazone site of HSA.2,15,72 HSA is believed to have at least one common
site for R- and S-ibuprofen,73–79 but S-ibuprofen may have at least one additional binding
region on this protein.79
Table 1 and Figure 6(a) show the results that were obtained for D/L-tryptophan. When using
the SMCC immobilization method, greater than baseline separation was achieved for these
analytes on an HSA column (resolution, Rs = 5.8; selectivity factor, α = 14.3). The
corresponding control column (with no HSA present) gave no chiral recognition and a retention
factor of 0.49 for D- and L-tryptophan (i.e., 32% and 2%, respectively, of the retention factors
noted for these same solutes on the SMCC HSA column). Figure 6(a) also shows some
chromatograms for injections of D/L-tryptophan on an HSA column that was prepared by the
SIA method. This SIA column gave a baseline separation for D- and L-tryptophan with a
resolution of 1.8 and a selectivity factor of 3.83. The SIA control column gave a retention factor
of 0.36 for D- and L-tryptophan (i.e., 63% and 16%, respectively, of the retention factors noted
on the SIA HSA column). The retention factor due to non-specific binding between D/L-
tryptophan and uncapped aminopropyl groups on the support was estimated to be 0.34, which
made up roughly 69% and 94% of the retention measured on the SMCC and SIA control
supports. However, it was found that this non-specific binding could be significantly reduced
(e.g., a ~ 60% reduction for warfarin and 20% for carbamazepine) by capping the aminopropyl
groups prior to HSA immobilization.
The results for the separation of R/S-warfarin on the various HSA columns are summarized in
Table 2. As shown in Figure 6(b), an HSA column produced by the SMCC method gave a
column with a baseline separation for R- and S-warfarin, as represented by a resolution of 1.81
and a selectivity factor of 1.66. The control SMCC column gave a retention factor of 1.55 for
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R- and S-warfarin (i.e., 4.4% and 2.7%, respectively, of the total retention noted for R- and S-
warfarin on the corresponding HSA column). Near baseline separation was also achieved for
R/S-warfarin when using the SIA method for HSA immobilization (resolution, 1.42; selectivity
factor, 1.53). In the SIA method, the retention factor for R- and S-warfarin on the control
column was 1.42 (i.e., 19% and 13%, respectively, of the retention noted on the SIA HSA
column). The retention factor due to non-specific binding between R/S-warfarin and
aminopropyl groups on the support was approximately 1.36, making up 88% and 96% of the
retention seen for R/S-warfarin on the SMCC and SIA control supports.
Table 3 shows the results obtained for R/S-ibuprofen. A baseline separation (resolution, 1.88;
selectivity factor, 1.66) was found for R/S-ibuprofen on an HSA column prepared by the SMCC
method. A control column for this same method gave a retention factor of 0.42 for these solutes
(i.e., 2.4% and 1.4%, respectively, of the retention noted for S- and R-ibuprofen on the HSA
column). R/S-Ibuprofen injected onto an HSA column prepared by the SIA method gave
baseline separation with a resolution of 1.51 and a separation factor of 1.43; the control column
in this method gave a retention factor of 0.38 (i.e., 9.4% and 6.6%, respectively, of the retention
noted for S- and R-ibuprofen on the SIA HSA column). Non-specific binding between R/S-
ibuprofen and aminopropyl groups on the support gave a retention factor of 0.35, or 83% and
92% of the retention seen for ibuprofen on the SMCC and SIA control supports.
For all three groups of these chiral solutes, HSA immobilized by the SMCC method gave a
higher resolution and selectivity factor than HSA that had been immobilized by the SIA
method. This greater separating power was mainly due to the higher retention factor that was
noted for all solutes in HSA columns prepared by the SMCC method. Although the SMCC
supports also gave a slightly higher degree of non-specific binding than the SIA method for
all tested solutes, this difference was minor compared to the difference in overall retention seen
in HSA columns made by these two techniques. One reason for the greater separating ability
of SMCC-prepared columns is the larger amount of HSA that was covalently attached to silica
in this method (i.e., 53.5 mg HSA/g silica versus 12.8 mg/g silica in the SIA method). However,
this factor alone accounted for only about a four-fold difference in retention. This is short of
the 4.9 to 11.5-fold differences in retention seen for D/L-tryptophan in HSA columns made by
the SMCC and SIA methods (after correcting for non-specific binding), and the subsequent
differences in retention of 4.8- to 5.4-fold for R/S-warfarin and 4.5- to 5.3-fold for R/S-
ibuprofen in these same columns. This is believed to reflect differences in the activities of the
SMCC and SIA immobilized HSA, as will be examined further in the following section.
Comparison with amine-based immobilization methods
The chiral separation results for both the SMCC and SIA methods were compared to those for
an amine-based immobilization technique, as represented here by the Schiff base method, using
the same starting support material and preparation of HSA. As shown in Table 1, the retention
of D-tryptophan in the SMCC-prepared HSA column was about 1.8-times higher than the
retention of this analyte on the HSA column made by the Schiff base method and 2.7-times
higher than that of the HSA column made using the SIA method. The retention of L-tryptophan
in SMCC-prepared HSA column was 2.5-times higher than that of the Schiff base column and
9.8-times higher than the SIA column.
These observed differences in retention for D- and L-tryptophan on the various HSA supports
were much larger than those predicted just based on the total content of HSA in each column.
For instance, the amount of protein on the SMCC support (53.5 mg/g silica) was only slightly
higher than that of the Schiff base column (49.4 mg/g silica) and 4.1-fold higher than that of
the SIA column (12.8 mg HSA/g silica). Thus, these measured differences in retention suggest
that there were also differences in the binding capacities and/or relative activities of these
immobilized HSA supports for D- and L-tryptophan. This conclusion was further supported
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by the differences in selectivity factor for D/L-tryptophan in these HSA columns, where the
SMCC-prepared HSA column gave a value that was 1.2-times higher than that for the Schiff
base column and 3.7-times higher than that for the SIA column. Similarly, the resolution of D/
L-tryptophan in SMCC column was 1.7-times higher than that for the Schiff base column and
3.2-times greater than that for the SIA column, although these latter differences could also
reflect differences in the band-broadening properties of these materials.
Some of the same trends were seen for R- and S-warfarin (see Table 2). In this case, the retention
for R-warfarin on the SMCC-prepared HSA column was 2.7-times greater than that of the
Schiff base column and 4.7-times higher than that of the SIA column, while the retention of
S-warfarin on the SMCC-prepared HSA column was 2.1- to 5.4-times higher than that of these
other columns. However, the selectivity factor for R/S-warfarin on the SMCC column was now
1.2-fold lower than that for the Schiff base column and only 1.2-times higher than that of the
SIA column. The resolution of R/S-warfarin on these columns gave the same type of pattern,
with the SMCC and Schiff base columns having similar resolutions and the SIA column having
a 1.2-fold lower value. This difference from the D/L-tryptophan results may be a result of the
fact that different binding sites on HSA are involved in interacting with these two groups of
analytes.1,19,44
When R/S-ibuprofen was used as the analyte, the retention of S-ibuprofen in the SMCC-
prepared HSA column was three-times higher than the retention seen for the Schiff base column
and four-times higher than the retention measured on the SIA column (see Table 3). The
retention of R-ibuprofen on SMCC column was three-times higher than on the Schiff base
column and five-times higher than on the SIA column. The selectivity factors and resolutions
for R/S-ibuprofen on the Schiff base and SMCC columns were similar and 1.2-times higher
than that seen for the SIA column.
The results in Tables 1–3 were examined more closely by normalizing each retention factor
for the protein content of the columns. This was accomplished by using the ratio of the retention
factor for each solute versus the total amount of HSA in the column, as shown in Tables 1–3
by the term “k/(μmol HSA)”. This type of ratio has been shown previously to be useful in
comparing the relative activity of affinity columns that contain different quantities of the same
ligand.38,40 As indicated in Table 1, studies performed with D-tryptophan (i.e., an injected
probe with weak retention) gave similar values for this ratio for HSA columns prepared by the
Schiff base and SMCC methods, with a 1.7-times lower ratio being obtained by the SIA method.
This indicated that HSA prepared by the Schiff base and SMCC method were slightly more
active for D-tryptophan than HSA that had been immobilized by the SIA method. The SMCC
results for L-tryptophan (i.e., an indole-benzodiazepine site probe with moderate retention)
gave a ratio that was two- to four-times higher that the ratios for the Schiff base and SIA
columns, respectively. This indicated that HSA immobilized by SMCC method was much more
active for L-tryptophan than HSA that had been coupled by the other two methods. The
different behavior noted here for L- versus D-tryptophan was not surprising since these two
enantiomers have been proposed to have different binding regions on HSA,44 These different
regions, in turn, may have been subject to different immobilization effects in these coupling
techniques, as has been suggested previously.40
For R/S-warfarin (i.e., warfarin-azapropazone site probes with high retention), the SMCC
method gave immobilized HSA with 1.6-times higher relative activity for R-warfarin than the
SIA method, and the SIA method gave 1.4-times higher relative activity than the Schiff base
method (see Table 2). For S-warfarin, SMCC method gave immobilized HSA with
approximately 1.8-times higher activity than both the Schiff base and SIA methods (see Table
2). A similar trend was noted for R/S-ibuprofen (see Table 3). The higher activity of the SMCC
versus SIA columns for L-tryptophan, warfarin and ibuprofen could be due, in part, to the
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longer spacer arm that was present in the SMCC method (8.67 Å versus 1.50 Å in the SIA
method). This latter feature may also explain some of the differences in non-specific binding
that were noted in these methods.
The differences between the SMCC and SIA methods versus the Schiff base method are
believed to be mainly due to the different types of functional groups on HSA that take part in
these immobilization methods. For instance, an amine-based method like the Schiff base
technique would involve coupling through the N-terminus of HSA or lysine residues, which
make up approximately 10% of the amino acids in HSA (59 out of 585 residues in HSA). In
contrast to this, there are only 35 cysteines in HSA (5.9% of all residues), with only one of
these (Cys-34) normally being present in a free form (i.e., not as part of a disulfide bond).42
Due to the much lower abundance of free cysteine groups in HSA as well as in other proteins
(e.g., the relative abundance of lysines in proteins is around 7% and for cysteines it is 2.8%),
80 it would be expected that the use of these sulfhydryl groups would result in an immobilized
protein that has a more well-defined orientation and better activity than a protein which has
been coupled through a more random or amine-based coupling method.
As noted earlier in this report, both the SMCC and SIA methods were found to react mainly
through the free cysteine group of HSA, although some reaction with other side chains may
also have been present. In the case of the SMCC method it was estimated that at least 81% of
the HSA was immobilized through sulfhydryl groups (i.e., Cys-34), while the remaining 19%
of HSA may have been immobilized through other nucleophilic residues. In the SIA method,
it was determined that approximately 77% of HSA was immobilized through sulfhydryl groups
and less than 23% through other residues. It was also noted that the immobilization of HSA
through sulfhydryl groups significantly increased the activity of this protein compared to HSA
prepared by the Schiff base method. For example, the relative activity of immobilized HSA
for carbamazepine in the SMCC and SIA methods was 81–87%, while the relative activity of
HSA for carbamazepine in the Schiff base method was only 55%.
Along with high activity, it is important in many studies to have low non-specific binding for
an analyte on an affinity support. As shown in Tables 1–3, all analytes considered in this study
gave the lowest degree of non-specific binding in the Schiff base method, with control columns
that gave only 0.5–1.2% (for L-tryptophan, R/S-ibuprofen and R-/S-warfarin) and 7.3% (for
D-tryptophan) of the retention seen on the HSA columns. Non-specific binding by these same
analytes was estimated to make up 1.4–4.7% (SMCC method) and 6.6–19% (SIA method) of
the total retention noted on HSA columns for L-tryptophan, R/S-ibuprofen and R/S-warfarin
and 32% (SMCC method) or 63% (SIA method) of the total retention measured for D-
tryptophan.
A final factor considered in comparing these immobilization methods was operational stability
of their final supports. This was examined by monitoring any change in the retention factors
of L-tryptophan and R/S-warfarin after passing 250 mL of mobile phase (i.e., 385 column
volumes) at 0.5 mL/min through columns containing these supports. The results indicated that
the SMCC method gave immobilized HSA with the highest stability, with a decrease in
retention of only 11–13% for all tested analytes. The second most stable material was SIA-
prepared HSA support, which gave a 12–18% decrease in retention factors. The Schiff base
method gave HSA supports that had the lowest stability, with a 15–48% decrease in retention
being noted. This latter observation could be a result of the use of sodium borohydride (a strong
reducing agent) during the Schiff base method, which might cause some reduction of disulfide
bonds in HSA and some slow changes in tertiary structure.
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CONCLUSIONS
This paper examined the preparation of maleimide- and iodoacetyl-activated silica by the
SMCC and SIA methods for the immobilization of proteins, using HSA as a model. The
resulting supports were characterized by such methods as frontal analysis, FTIR, elemental
analysis and a papain-based assay. The specific activity of the immobilized HSA for
carbamazepine was found to be 81–87% for the SMCC and SIA methods, which was much
greater than for HSA that had been coupled to silica through an amine-based technique (i.e..,
55% activity when using the Schiff base method). Furthermore, the selectivity of the SIA and
SMCC methods for free sulfhydryl groups on a protein was estimated to be between 77 and
81%, based on results obtained using normal and iodoacetylated HSA.
HSA supports prepared by the SMCC, SIA and Schiff base methods were also compared in
terms of their retention and ability to separate chiral substances such as D/L-tryptophan, R/S-
warfarin and R/S-ibuprofen. It was found that the SMCC and SIA methods gave HSA supports
with comparable or improved activity and stability versus HSA columns made by the Schiff
base method, with the SMCC method giving the best overall behavior. These features should
make the SMCC and SIA methods useful for work with other proteins or sulfhydryl-containing
ligands and offer the potential of giving greater site-selective immobilization and activity than
amine-based coupling methods. This makes these techniques attractive for the development of
protein columns for such analytical applications as the study of biological interactions and
chiral separations. It should also be possible to adapt these methods for use with alternative
proteins and other materials based on silica or glass when it is desired to couple ligands to such
supports through sulfhydryl groups.
Acknowledgements
This work was supported by the National Institutes of Health under grants R01 GM044931 and R01 DK069629. This
work was performed in facilities that were remodeled under NIH grant RR015468-001.
References
1. Hage DS, Austin J. J Chromatogr B 2000;739:39–54.
2. Hage DS. J Chromatogr B 2002;768:3–30.
3. Larive CK, Lunte SM, Zhong M, Perkins MD, Wilson GS, Gokulrangan G, Williams T, Afroz F,
Schoeneich C, Derrick TS, Middaugh CR, Bogdanowich-Knipp S. Anal Chem 1999;71:389R–423R.
4. Lillehoj EP, Malik VS. Adv Biochem Engin Biotech 1989;40:19–71.
5. Chattopadhyay A, Tian T, Kortum L, Hage DS. J Chromatogr B 1998;715:183–190.
6. Liu Y, Zhao R, Shangguan D, Zhang H, Liu G. J Chromatogr B 2003;792:177–185.
7. Yang J, Hage DS. J Chromatogr 1993;645:241–250. [PubMed: 8408417]
8. Clonis YD. J Chromatogr A 2006;1101:1–24. [PubMed: 16242704]
9. Sun X, Chiu JF, He QY. Expert Rev Proteomics 2005;2:649–657. [PubMed: 16209645]
10. Voit R. BIOspektrum 2005;11:337–339.
11. Linhult M, Guelich S, Hober S. Prot Peptide Lett 2005;12:305–310.
12. Cuatrecasas P, Wilchek M. Encyclopedia Biol Chem 2004;1:51–56.
13. Schriemer DC. Anal Chem 2004;76:440A–448A.
14. Jungbauer A, Hahn R. Curr Opin Drug Discov Develop 2004;7:248–256.
15. Hage DS, Tweed SA. J Chromatogr B 1997;699:499–525.
16. Chaiken, IM., editor. Analytical Affinity Chromatography. CRC Press; Boca Raton: 1987.
17. Scouten, WH. Affinity Chromatography: Bioselective Adsorption on Inert Matrices. Wiley; New
York: 1981.
18. Turkova, J. Affinity Chromatography. Elsevier; Amsterdam: 1978.
Mallik et al. Page 15
Anal Chem. Author manuscript; available in PMC 2008 September 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
19. Loun B, Hage DS. Anal Chem 1996;68:1218–1225. [PubMed: 8651495]
20. Bjoerklund M, Hearn MTW. J Chromatogr A 1996;743:145–162. [PubMed: 8817878]
21. Hornsey VS, Prowse CV, Pepper DS. J Immunol Methods 1986;93:83–88. [PubMed: 3021857]
22. Stults NL, Asta LM, Lee YC. Anal Biochem 1989;180:114–119. [PubMed: 2554747]
23. Suda Y, Nakamura M, Koshida S, Kusumoto S, Sobel M. J Bioactive Compatible Polymers
2000;15:468–477.
24. Suzuki N, Quesenberry MS, Wang JK, Lee RT, Kobayashi K, Lee YC. Anal Biochem 1997;247:412–
416. [PubMed: 9177706]
25. Thomas DH, Beck-Westermeyer M, Hage DS. Anal Chem 1994;66:3823–3829.
26. Frey T, Cosio EG, Ebel J. Phytochem 1993;32:543–550.
27. Burton SJ, Stead CV, Lowe CR. J Chromatogr 1990;508:109–125. [PubMed: 2380311]
28. Koyama T, Terauchi KI. J Chromatogr B 1996;679:31–40.
29. Potempa LA, Motie M, Anderson B, Klein E, Baurmeister U. Clin Materials 1992;11:105–117.
30. Sudi P, Dala E, Szajani B. Appl Biochem Biotech 1989;22:31–43.
31. Taylor RF. Anal Chim Acta 1985;172:241–248.
32. Kim, HS.; Hage, DS. Handbook of Affinity Chromatography. Hage, DS., editor. CRC Press; Boca
Raton: 2005. p. 35-78.
33. Hermanson, GT. Bioconjugate Techniques. Acedemic Press; San Diego: 1995.
34. Berruex LG, Freitag R, Tennikova TB. J Pharmaceut Biomed Anal 2000;24:95–104.
35. Gupalova TV, Lojkina OV, Palagnuk VG, Totolian AA, Tennikova TB. J Chromatogr A
2002;949:185–193. [PubMed: 11999734]
36. Jiang T, Mallik R, Hage DS. Anal Chem 2005;77:2362–2372. [PubMed: 15828768]
37. Luo Q, Zou H, Zhang Q, Xiao X, Ni J. Biotechnol Bioengin 2002;80:481–489.
38. Mallik R, Jiang T, Hage DS. Anal Chem 2004;76:7013–7022. [PubMed: 15571354]
39. Ostryanina ND, Vlasov GP, Tennikova TB. J Chromatogr A 2002;949:163–171. [PubMed:
11999732]
40. Kim HS, Kye YS, Hage DS. J Chromatogr A 2004;1049:51–61. [PubMed: 15499917]
41. Kragh-Hansen U. Pharmacol Rev 1981;33:17–53. [PubMed: 7027277]
42. Peters, TJ. All About Albumin: Biochemistry, Genetics and Medical Applications. Academic Press;
San Diego: 1995.
43. Sengupta A, Hage DS. Anal Chem 1999;71:3821–3827. [PubMed: 10489529]
44. Yang J, Hage DS. J Chromatogr A 1997;766:15–25. [PubMed: 9134727]
45. Hashida S, Imagawa M, Inoue S, Ruan KH, Ishikawa E. J Appl Biochem 1984;6:56–63. [PubMed:
6490581]
46. Partis MD, Griffiths DG, Roberts GC, Beechey RB. J Protein Chem 1983;2:263–277.
47. Rector ES, Schwenk RJ, Tse KS, Sehon AH, Chan H. J Immunol Methods 1978;24:321–336.
[PubMed: 102705]
48. Thorpe PE, Ross WCJ, Brown ANF, Myers CD, Cumber AJ, Foxwell BMJ, Forrester JT. Eur J
Biochem 1984;140:63–71. [PubMed: 6608447]
49. Yoshitake S, Imagawa M, Ishikawa E, Niitsu Y, Urushizaki I, Nishiura M, Kanazawa R, Kurosaki
H, Tachibana S, et al. J Biochem 1982;92:1413–1424. [PubMed: 6759501]
50. Rezania A, Johnson R, Lefkow AR, Healy KE. Langmuir 1999;15:6931–6939.
51. Tada T, Mano K, Yoshida E, Tanaka N, Kunugi S. Bull Chem Soc Japan 2002;75:2247–2251.
52. Tournier EJM, Wallach J, Blond P. Anal Chim Acta 1998;361:33–44.
53. Larsson PO. Methods Enzymol 1984;104:212. [PubMed: 6371445]
54. Brinkley M. Bioconj Chem 1992;3:2–13.
55. Domen PL, Nevens JR, Mallia AK, Hermanson GT, Klenk DC. J Chromatogr 1990;510:293–302.
[PubMed: 2401701]
56. Singh R. Bioconj Chem 1994;5:348–351.
57. Singh R, Blaettler WA, Collinson AR. Methods Enzymol 1995;251:229–237. [PubMed: 7651201]
Mallik et al. Page 16
Anal Chem. Author manuscript; available in PMC 2008 September 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
58. Singh R, Blattler WA, Collinson AR. Anal Biochem 1993;213:49–56. [PubMed: 8238881]
59. Rollag JG, Beck-Westermeyer M, Hage DS. Anal Chem 1996;68:3631–3637.
60. Williams ML, Wainer IW. Therap Drug Monit 2002;24:290–296. [PubMed: 11897974]
61. Patel, S.; Wainer, IW.; Lough, WJ. Handbook of Affinity Chromatography. Hage, DS., editor. CRC
Press; Boca Raton: 2005. p. 571-594.
62. Allenmark, SG. Chromatographic Enantioseparation Methods and Applications. Ellis Horwood;
Chichester, UK: 1988.
63. Hayball PJ, Holman JW, Nation RL. J Chromatogr B 1994;662:128–133.
64. Anderson DJ, Walters RR. J Chromatogr Sci 1984;22:353–359.
65. Pretsch, E.; Buehlmann, P.; Affolter, C. Structure Determination of Organic Compounds: Tables of
Spectral Data. Springer; Berlin: 2003.
66. Jarret HW. J Chromatogr 1987;405:179–189.
67. Chen J, Ohnmacht C, Hage DS. J Chromatogr B 2004;809:137–145.
68. Wa C, Cerny R, Hage DS. Anal Biochem 2006;349:229–241. [PubMed: 16356458]
69. Kim HS, Hage DS. J Chromatogr B 2005;816:57–66.
70. Kim HS, Mallik R, Hage DS. J Chromatogr B 2006;837:138–146.
71. Muller WE, Wollert U. Naunyn-Schmiedeberg’s Arch Pharmacol 1975;288:17–27.
72. Fehske KJ, Mueller WE. Pharmacol 1986;32:208–213.
73. Rahman MH, Yamasaki K, Shin YH, Lin CC, Otagiri M. Biol Pharmaceut Bull 1993;16:1169–1174.
74. Domenici E, Bertucci C, Salvadori P, Motellier S, Wainer IW. Chirality 1990;2
75. Watanabe H, Yamasaki K, Kragh-Hansen U, Tanase S, Harada K, Suenaga A, Otagiri M. Pharmaceut
Res 2001;18:1775–1781.
76. Cheruvallath VK, Riley CM, Narayanan SR, Lindenbaum S, Perrin JH. Pharmaceut Res 1996;13:173–
178.
77. Chen J, Fitos I, Hage DS. Chirality 2005;18:24–36. [PubMed: 16278829]
78. Kim HS, Austin J, Hage DS. Electrophoresis 2002;23:956–963. [PubMed: 11920883]
79. Hage DS, Noctor TAG, Wainer IW. J Chromatogr A 1995;693:23–32. [PubMed: 7697161]
80. Garrett, R.; Grisham, CM. Biochemistry. 2. Saunders; Fort Worth: 1999.
81. Smith, P. K.; (Pierce Chemical Co., USA). Application: US, 1989, 2 pp, Cont of U S Ser No 618,727,
abandoned.
82. Walker, JM. Protein Protocols Handbook. 2. 2002. p. 11-14.
83. Zaia DAM, Zaia CTBV, Lichtig J. Quimica Nova 1998;21:787–793.
84. Walker JM. Methods Mol Biol 1994;32:5–8. [PubMed: 7951748]
Mallik et al. Page 17
Anal Chem. Author manuscript; available in PMC 2008 September 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Reactions involved in the (a) SMCC method and (b) SIA method, using aminopropyl silica as
the starting material. Abbreviations: SMCC, N-(4-carboxycyclohexylmethyl) maleimide; SIA,
succinimidyl iodoacetate; DMAP, 4-dimethylaminopyridine; DMF, dimethylformamide;
EDTA, ethylenediamine tetraacetic acid; KPB, potassium phosphate buffer.
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Figure 2.
Determination of the amount of active maleimide and iodoacetyl groups on silica by a papain-
based assay. In the first step of (a) excess cysteine is added to the activated support and allowed
to react. In the second step of (a), inactive papain is added to the reaction mixture, allowing
conversion of papain to its active form as it undergoes a disulfide exchange reaction with
residual cysteines. In (b), the active papain is measured by allowing it to convert its substrate
L-BAPNA to the product p-nitroanilide. Absorbance of the product p-nitroanilide is then
measured at 410 nm.
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Figure 3.
IR spectra of (a) aminopropyl silica (b) maleimide-activated silica (SMCC method) (c)
iodoacetyl-activated silica (SIA method). See the text for assignment of the peaks.
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Figure 4.
Amount of HSA immobilized at various reaction times and at 4°C when using silica that had
been activated by the SMCC or SIA methods. In this study the original sample contained 0.15
g of activated silica plus 1.5 mL of a 15 mg/mL HSA solution in the immobilization buffer or
1.5 mL of the immobilization buffer with no protein present. After a given reaction time, a 20
μL aliquot of this mixture was withdrawn and centrifuged, with the protein content of the
supernatant then being measured by using a BCA protein assay.81–84 The final amount of
protein on the maleimide-activated silica (SMCC method) or iodoacetyl-activated silica (SIA
method) was determined using a reducing agent compatible BCA assay. These particular
studies were performed using activated supports in which the aminopropyl groups had not been
capped with acetic anhydride; the presence of these aminopropyl groups gave rise to the
adsorption of 14.3 mg HSA/g silica after a reaction time of 52 h.
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Figure 5.
Frontal analysis studies for carbamazepine on HSA columns prepared by the (a) SMCC method
or (b) SIA method. In the double-reciprocal plots shown at the bottom of this figure, mLapp is
the apparent moles of solute (carbamazepine) that is required to reach the mean point of the
breakthrough curve at a given concentration of the applied solute. The equations for the best-
fit lines in these latter plots were as follows: (a) Y = {2.42 (± 0.01) × 102} X + 2.8 (± 0.3) ×
106, with a correlation coefficient of 0.999 (n = 5); (b) Y = {6.8 (± 0.2) × 102} X + 1.1 (± 0.5)
× 107, with a correlation coefficient of 0.996 (n = 5).
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Figure 6.
Chromatograms for injections of (a) D/L-tryptophan, (b) R/S-warfarin and (c) R/S-ibuprofen
on HSA columns prepared by the SMCC and SIA methods. The conditions were as follows:
sample concentration, 20 μM tryptophan, ibuprofen, or warfarin; sample volume, 20 μL;
mobile phase for tryptophan, pH 7.4, 0.067 M potassium phosphate buffer; mobile phase for
ibuprofen, pH 7.0, 0.067 M potassium phosphate buffer containing 8% isopropanol and 5 mM
octanoic acid; mobile phase for warfarin, pH 7.0, 0.067 M potassium phosphate buffer
containing 5% isopropanol and 1 mM octanoic acid; flow rate for SMCC-HSA column, 1.5
mL/min for tryptophan, 1.0 mL/min for ibuprofen and warfarin; flow rate for SIA-HSA
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column, 0.3 mL/min for tryptophan and warfarin, 0.5 mL/min for ibuprofen; column size, 5
cm × 4.6 mm I.D.; temperature, 25°C.
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